Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

G. Curigliano · SciRah

Researcher profile · Semantic Scholar

G. Curigliano

Share profile

G. Curigliano — researcher profile on SciRah

h-index: 92
Works: 864
Citations: 43K

Most-cited papers

Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline
I. Bedrosian, M. Somerfield, M. Achatz, J. Boughey +15 more
2024Journal of Clinical Oncology187 citations
Semantic Scholar
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
R. Leon-Ferre, S. Jonas, R. Salgado, S. Loi +29 more
2024Journal of the American Medical Association (JAMA)186 citations Open access
Semantic Scholar
Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial
S. Loi, R. Salgado, G. Curigliano, Roberto Iván Romero Díaz +22 more
2025Nature Medicine117 citations Open access
Semantic Scholar
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.
Bob T. Li, F. Meric-Bernstam, A. Bardia, Y. Naito +16 more
2024The Lancet Oncology92 citations
Semantic Scholar
Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breas
G. Curigliano, Xi-Chun Hu, R. Dent, K. Yonemori +14 more
2024Journal of Clinical Oncology90 citations
Semantic Scholar
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial
S. Hurvitz, S.-B. Kim, W. Chung, S.-A. Im +17 more
2024ESMO Open78 citations Open access
Semantic Scholar
Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy
D. Izzo, L. Ascione, L. Guidi, R. Marsicano +3 more
2025Therapeutic Advances in Medical Oncology64 citations Open access
Semantic Scholar
Emerging treatments in HER2-positive advanced breast cancer: Keep raising the bar
E. Agostinetto, G. Curigliano, M. Piccart
2024Cell Reports Medicine50 citations Open access
Semantic Scholar
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer
D. Massa, C. Vernieri, Lorenzo Nicolè, C. Criscitiello +19 more
2024Journal of the National Cancer Institute38 citations Open access
Semantic Scholar
Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer
S. Morganti, Christopher J. Gibson, Q. Jin, K. Santos +19 more
2024Journal of Clinical Oncology35 citations Open access
Semantic Scholar
HER2DX genomic test in early-stage HER2-positive breast cancer
S. Tolaney, N. Tung, A. Wolff, A. Demichele +11 more
2024ESMO Open33 citations Open access
Semantic Scholar
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer
P. Schmid, M. Oliveira, J. O'Shaughnessy, M. Cristofanilli +11 more
2025Therapeutic Advances in Medical Oncology31 citations Open access
Semantic Scholar
Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact.
K. Venetis, Chiara Frascarelli, L. Bielo, Giulia Cursano +15 more
2025European Journal of Cancer30 citations
Semantic Scholar
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial
A. Okines, G. Curigliano, N. Mizuno, Do-Youn Oh +27 more
2025Nature Medicine28 citations Open access
Semantic Scholar
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer.
Luca Boscolo Bielo, D. Trapani, E. Nicolò, C. Valenza +9 more
2024Cancer Treatment Reviews27 citations
Semantic Scholar
Abstract GS01-10: HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer
S. Hurvitz, S. Loi, J. O'Shaughnessy, A. Okines +26 more
2024Cancer Research24 citations
Semantic Scholar
Invasive lobular breast cancer: Focus on prevention, genetics, diagnosis, and treatment.
Giovanni Corso, Nicola Fusco, E. Guerini-Rocco, M. Leonardi +30 more
2024Seminars in Oncology22 citations
Semantic Scholar
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2–Negative Metastatic Breast Cancer
P. B. Berton Giachetti, S. Morganti, S. Gandini, Fabiola Giudici +28 more
2025JAMA Network Open21 citations Open access
Semantic Scholar
Abstract GS01-01: Biomarker Results in High-risk Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Primary Breast Cancer Following Neoadjuvant Chemotherapy ± Nivolumab: an Exploratory Analysis of CheckMate 7FL
S. Loi, G. Curigliano, R. Salgado, R. Diaz +17 more
2024Cancer Research21 citations
Semantic Scholar
Circulating tumor cells et al.: towards a comprehensive liquid biopsy approach in breast cancer
E. Nicolò, C. Gianni, L. Pontolillo, M. Serafini +5 more
2024Translational Breast Cancer Research21 citations Open access
Semantic Scholar
Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies.
F. Giugliano, C. de Angelis, B. Pistilli, G. Viale +9 more
2025Cancer Treatment Reviews20 citations Open access
Semantic Scholar
BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2− breast cancer (BC).
D. Juric, M. Patel, L. Duska, K. Jhaveri +13 more
2024Journal of Clinical Oncology19 citations Open access
Semantic Scholar
Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and Immunotherapy.
C. Corti, Busem Binboğa Kurt, B. Koca, Tasnim Rahman +10 more
2024Cancer Treatment Reviews17 citations Open access
Semantic Scholar
Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations
L. Bielo, E. Rocco, D. Trapani, P. Zagami +10 more
2024ESMO Open16 citations Open access
Semantic Scholar
Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer
Á. Quintana, K. Saini, L. Vidal, V. Peg +5 more
2024ESMO Open16 citations Open access
Semantic Scholar
Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined With Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies.
J. Luke, K. Gelmon, L. Siu, Víctor Moreno +16 more
2024Clinical Cancer Research16 citations
Semantic Scholar
Policy strategies for capacity building and scale up of the workforce for comprehensive cancer care: a systematic review
D. Trapani, S. Murthy, N. Hammad, R. Casolino +5 more
2024ESMO Open15 citations Open access
Semantic Scholar
Antibody-drug conjugates in metastatic breast cancer: sequencing, combinations and resistances
L. Guidi, Laura Boldrini, D. Trapani, G. Curigliano
2024Current Opinion in Oncology14 citations
Semantic Scholar
Biomarkers for antibody-drug conjugates in solid tumors.
J. Katrini, Laura Boldrini, C. Santoro, C. Valenza +2 more
2024Molecular Cancer Therapeutics14 citations
Semantic Scholar
Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancer.
R. Bartsch, D. Cameron, E. Ciruelos, C. Criscitiello +9 more
2024Cancer Treatment Reviews13 citations Open access
Semantic Scholar
Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer.
L. Licata, M. Dieci, C. de Angelis, C. Marchiò +8 more
2024Cancer Treatment Reviews13 citations Open access
Semantic Scholar
Deep learning algorithm on H&E whole slide images to characterize TP53 alterations frequency and spatial distribution in breast cancer
Chiara Frascarelli, K. Venetis, Antonio Marra, Eltjona Mane +10 more
2024Computational and Structural Biotechnology Journal13 citations Open access
Semantic Scholar
Expert consensus on the prevention of brain metastases in patients with HER2-positive breast cancer.
V. Müller, T. Bachelot, G. Curigliano, E. de Azambuja +9 more
2024Cancer Treatment Reviews12 citations Open access
Semantic Scholar
Comparison of long-term outcome between clinically high risk lobular versus ductal breast cancer: a propensity score matched study
F. Magnoni, Giovanni Corso, Patrick Maisonneuve, B. Bianchi +11 more
2024EClinicalMedicine12 citations Open access
Semantic Scholar
Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: challenges and future perspectives
L. Ascione, G. Castellano, G. Curigliano, P. Zagami
2024Current Opinion in Oncology12 citations
Semantic Scholar
Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer.
A. Bardia, Maria Schwaederle, G. Curigliano
2025New England Journal of Medicine11 citations
Semantic Scholar
Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03.
E. Hamilton, S. Hurvitz, Seock-Ah Im, H. Iwata +16 more
2024Journal of Clinical Oncology11 citations
Semantic Scholar
Climate Therapy: Sustainability Solutions for Breast Cancer Care in the Anthropocene Era.
S. O'Reilly, Emer Lynch, E. Hwang, Maura J. Brown +10 more
2024Clinical Breast Cancer10 citations Open access
Semantic Scholar
Clinician’s guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer
Marya Hussain, C. Brezden-Masley, S. Chia, G. Curigliano +2 more
2025Therapeutic Advances in Medical Oncology9 citations Open access
Semantic Scholar
PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores.
M. Ivanova, Chiara Frascarelli, B. Cerbelli, M. G. Pignataro +10 more
2024Human Pathology9 citations
Semantic Scholar
The emerging role of Artificial Intelligence in proton therapy: a review.
L. Isaksson, F. Mastroleo, M. Vincini, G. Marvaso +22 more
2024Critical reviews in oncology/hematology9 citations Open access
Semantic Scholar
Molecular tumor board in patients with metastatic breast cancer
Luca Boscolo Bielo, Elena Guerini Rocco, E. Crimini, M. Repetto +17 more
2024Breast Cancer Research and Treatment9 citations
Semantic Scholar
A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies
G. Curigliano, M. Jiménez, T. Shimizu, B. Keam +14 more
2024ESMO Open9 citations Open access
Semantic Scholar
Use of Antibody–Drug Conjugates in the Early Setting of Breast Cancer
Chrysanthi Koukoutzeli, D. Trapani, L. Ascione, E. Kotteas +3 more
2024Clinical Medicine Insights: Oncology9 citations Open access
Semantic Scholar
An update on promising and emerging protein kinase B/AKT inhibitors for breast cancer
R. Asnaghi, G. Antonarelli, E. Battaiotto, G. Castellano +5 more
2025Expert Opinion on Pharmacotherapy8 citations Open access
Semantic Scholar
Biomarker and pharmacodynamic activity of the transforming growth factor‐beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors
D. Robbrecht, J. Grob, O. Bechter, Matteo Simonelli +19 more
2024Clinical and Translational Science8 citations Open access
Semantic Scholar
Developing combination therapies with biologics in triple-negative breast cancer
G. Gaudio, E. Martino, G. Pellizzari, Matteo Cavallone +5 more
2024Expert Opinion on Biological Therapy7 citations Open access
Semantic Scholar
INAVO122: A phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients (pts) with PIK3CA-mutated, HER2-positive advanced breast cancer (HER2+ aBC).
S. Swain, C. Barrios, R. Basho, G. Curigliano +12 more
2024Journal of Clinical Oncology7 citations
Semantic Scholar
Abstract PS08-09: Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE)
P. Tarantino, M. Hughes, Ross J. Kusmick, L. Alder +23 more
2024Cancer Research7 citations
Semantic Scholar
Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response.
C. Valenza, D. Trapani, S. Loibl, S. Chia +2 more
2024Journal of Clinical Oncology7 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

C. Criscitiello×14
Invite
C. Criscitiello — researcher profile on SciRah
D. Trapani×13
Invite
D. Trapani — researcher profile on SciRah
S. Loi×7
Invite
S. Loi — researcher profile on SciRah
Nicola Fusco×7
Invite
Nicola Fusco — researcher profile on SciRah

×6

Invite

C. Saura — researcher profile on SciRah

Invite

P. Zagami — researcher profile on SciRah

Invite

S. Tolaney — researcher profile on SciRah

Antonio Marra×5

Invite

Antonio Marra — researcher profile on SciRah

Invite

L. Guidi — researcher profile on SciRah

Beatrice Taurelli Salimbeni×4

Invite

Beatrice Taurelli Salimbeni — researcher profile on SciRah

Invite

K. Venetis — researcher profile on SciRah

G. Bianchini×4

Invite

G. Bianchini — researcher profile on SciRah